JonesTrading changed EyePoint Pharmaceuticals' rating to Hold after its stock fluctuated and its DURAVYU trial didn't succeed.
Good or bad for EYPT?
This is a Prominent story. The full analysis, including whether it is good or bad for EYPT, is available with Pro or after its release time. It opens to free readers on Nov 2, 2026, 9:29 AM ET.
Get alerts for EYPT
Follow EyePoint Pharmaceuticals (EYPT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EYPTFree on the App Store and Google Play, or on the web.